Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Seikagaku: Strong Domestic Sales Offset Weak Overseas Sales
November 22, 2010
- MSD Transfers 6 Long-Listed Products to Nichi-Iko
November 22, 2010
- Eisai Reports Positive PIII Results in Obese T2D Patients
November 22, 2010
- JCR: Agreement with GSK Props Up Business
November 22, 2010
- Seikagaku Aims at Sales of ¥30.5 Bil. in FY2011
November 22, 2010
- LTT Bio-Pharma Adds CSC Differentiation Inducer to Its R&D Pipeline
November 22, 2010
- Wakamoto: Sales Down 5.0% Due to NHI Price Cuts
November 22, 2010
- Tsumura Diversifies Crude Drugs Procurement Sources
November 22, 2010
- Korosho Kicks Off Research Team to Increase Popularity of Switch OTC Drugs
November 22, 2010
- Meiji Seika: Sales Up 10.4% Driven by Generics
November 22, 2010
- Kyowa Kirin: Pharma Sales Up 0.7%
November 22, 2010
- Teva-Kowa, Taisho Pharm. Ind. Integrate R&D Divisions
November 22, 2010
- Teijin: Pharma Sales Up 2.2%
November 22, 2010
- Astellas Sues Nycomed US to Protect Protopic Patents
November 22, 2010
- Sawai Proposes Business Integration to Kyorin
November 22, 2010
- Otsuka HD to Go Public in December
November 22, 2010
- TMX-67 to Be Launched in Japan after Spring 2011
November 22, 2010
- Takeda Accelerates Investment in Bioventures
November 22, 2010
- Takata to Comarket Ecbarl with Shionogi
November 22, 2010
- Asahi Kasei Pharma: Sales Remain Flat Despite Strong Sales of Recomodulin
November 22, 2010
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…